slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,539
Current window 92,281-92,310
Pages 3,685
Rows per page 30
Component
92,281-92,310 of 110,539
17
Lion Electric | Investor Presentation Deck | 31 slidesLion Electric | Investor Presentation Deck | 31 slides · Lion Electric
Pitch deck Investor relations Beat · FinancialsLoop · Quick Win Big Bet1 hit
18
Includes a disclaimer regarding non-IFRS measures at the bottom.Lion Electric | Investor Presentation Deck | 31 slides · Lion Electric
Pitch deck Investor relations Beat · FinancialsLoop · Quick Win Big Bet1 hit
19
Lion Electric | Investor Presentation Deck | 31 slidesLion Electric | Investor Presentation Deck | 31 slides · Lion Electric
Pitch deck Investor relations Beat · FinancialsLoop · Quick Win Big Bet1 hit
22
Includes detailed footnotes explaining adjustments to net earnings.Lion Electric | Investor Presentation Deck | 31 slides · Lion Electric
Pitch deck Investor relations 1 hit
24
Contains specific references to MD&A sections and regulatory filings.Lion Electric | Investor Presentation Deck | 31 slides · Lion Electric
Pitch deck Investor relations 1 hit
05
The slide uses a numbered list format to present value drivers, each paired with a specific financial or operational metric.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank Beat · ProblemLoop · Why Now1 hit
08
The slide uses a logo-grid to demonstrate market reach and lists three core pillars of their business model.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank Beat · Business Model1 hit
10
The slide uses a comparative structure to demonstrate the efficacy of the operating model across two distinct distribution strategies.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank Beat · Business Model1 hit
13
The slide serves as a business segment overview for 3 Arts Entertainment within a larger Lionsgate deck.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
22
Includes detailed footnotes explaining valuation assumptions and share counts.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank Beat · FinancialsLoop · Benchmark Gap1 hit
23
The slide illustrates a complex corporate spin-off/acquisition structure involving SPAC and PIPE investors.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank Beat · FinancialsLoop · Benchmark Gap1 hit
03
The slide uses a 2x3 grid layout to present key company pillars.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Loop · Golden Circle1 hit
06
Includes a process flow diagram for the test journey and product imagery.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
07
The slide outlines the technical workflow from sample collection to diagnostic output.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
10
The slide uses a visual timeline/process flow to explain the biological progression of the disease.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
11
The slide uses data from a 2022 JNCI study to justify the clinical importance of AA detection sensitivity.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
14
The table compares two distinct clinical trials (ColoFuture and eAArly DETECT) across key performance metrics.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
23
The slide uses a grid-like layout to present six key value propositions surrounding a central product image.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Investment Ask1 hit
09
The slide uses a biological process flow to explain the mechanism of action.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
11
Includes study references and definitions for GPR119, MASH, GLP-1, and drug dosages.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
12
The slide presents 11 distinct bar charts summarizing a study on drug efficacy in a mouse model of MASH (Metabolic dysfunction-associated steatohepatitis).NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations 1 hit
14
The slide uses a hub-and-spoke diagram to illustrate the multi-faceted mechanism of action of the drug target.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
17
The slide uses a hub-and-spoke diagram to illustrate the systemic effects of oxyntomodulin.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
20
Includes study design, population, and location details.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
06
The slide uses a biological mechanism-of-action diagram to illustrate how the two components of PrimeC address specific cellular stressors in ALS.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Agitate1 hit
10
Includes study design parameters (NST002) and key clinical outcomes.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
18
The slide uses a list of icons to anchor the clinical impact of the ALSFRS-R scale.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
22
The slide highlights the PARADIGM trial's research pillars, including proteomics, microRNA, exosomes, and neurofilaments, in partnership with institutions like MGH and Harvard.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
23
The slide uses a 'Case Study' to validate the company's own strategy of combination therapy.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
26
The slide outlines the methodology for a Phase 2 clinical trial for Alzheimer's Disease (AD).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit